Key result
Percutaneous balloon aortic valvuloplasty as a bridge to TAVI had a 6.4% periprocedural adverse event rate, and 46% of bridge patients subsequently became eligible for TAVI.
Why the study?
Does percutaneous balloon aortic valvuloplasty serve as an effective bridge to TAVI in patients with severe aortic stenosis who are not immediately eligible?
Observational (n=210)
No
Does percutaneous balloon aortic valvuloplasty serve as an effective bridge to TAVI in patients with severe aortic stenosis who are not immediately eligible?
Answers are grounded in this paper and cite their sources.
Balloon aortic valvuloplasty is a safe and effective strategy to bridge selected high-risk patients with severe aortic stenosis to TAVI or surgical valve replacement.
AIMS: Many inoperable patients with severe aortic stenosis (AS) are not immediately eligible for transcatheter aortic valve implantation (TAVI). We evaluated the role of percutaneous balloon aortic valvuloplasty (BAV) in this setting. METHODS AND RESULTS: Among 210 consecutive patients referred to our institution for BAV, we identified three groups: immediately eligible for TAVI (n=65, 31%), excluded from TAVI (n=67, 32%), BAV as a bridge to TAVI (n=78, 37%). This last group comprised patients with low left ventricular ejection fraction, frailty or enfeebled status, symptoms of uncertain origin, critical conditions, moderate-to-severe mitral valve regurgitation, need of major non-cardiac surgery. Outpatient clinic visit and echocardiography were performed around one month after BAV to decide the final therapeutic strategy. Mean age was 81±8 years and the vast majority of patients had comorbidities and high-risk features. The incidence of periprocedural adverse events was 6.4%: 5.1% death (four patients: one procedural complication, three, natural disease progression), 1.3% minor stroke. After BAV, 46% of these patients were deemed eligible for TAVI, and 28% for cardiac surgery. Patients who underwent TAVI after bridge BAV showed 94% 30-day survival. CONCLUSIONS: BAV is a safe and effective tool to bridge selected patients to TAVI when indications are not obvious.
No takes yet. Share an insight, caveat, or question.
Saia et al. (2011) conducted an observational in Severe aortic stenosis (n=210). Percutaneous balloon aortic valvuloplasty was evaluated on Periprocedural adverse events. Percutaneous balloon aortic valvuloplasty as a bridge to TAVI had a 6.4% periprocedural adverse event rate, and 46% of bridge patients subsequently became eligible for TAVI.
Synapse has enriched 10 related papers. Consider them for comparative context: